BGB-3111: Phase I started

BeiGene began an open-label, dose-escalation, dose-expansion, Australian Phase I trial to evaluate IV BGB-A317 every 3 weeks plus oral BGB-3111 in about 25 patients. BeiGene’s BGB-A317 is a humanized...